Plain-English translation of NCT06747949 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term follow-up study for people with Sjögren's syndrome who already participated in an earlier trial of , an experimental medication designed to help reduce symptoms. If you completed one of the earlier studies, you can continue receiving the medication for up to 2.5 additional years while doctors carefully monitor how safe and well-tolerated it is over the long term.
Sjögren's syndrome is a chronic condition that needs long-term treatment, but we don't yet have enough information about how this medication performs and whether it remains safe when people take it for extended periods. This study gathers that crucial safety data.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the same medication you may have been taking in the earlier study, continuing for an additional 132 weeks (about 2.5 years). You'll visit the research clinic regularly so the study team can check your safety through blood tests, physical exams, and symptom assessments. The study is open-label, meaning both you and your doctor will know you're receiving the active medication.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States